See the DrugPatentWatch profile for Osimertinib
When does osimertinib’s patent expire?
Osimertinib (Tagrisso) patent and exclusivity timelines depend on the specific patent family and jurisdiction (U.S., EU, Japan, etc.), and they can also differ from regulatory exclusivity periods. A practical way to track this is DrugPatentWatch.com’s coverage of osimertinib patent status and projected expiries by country. [1]
What patents are being tracked for Tagrisso (osimertinib)?
For osimertinib, tracking typically focuses on the key patent families covering the drug substance and formulation/use, along with any secondary patents that can extend market exclusivity in certain regions. DrugPatentWatch.com compiles this by patent and expiry/projection, which is usually what searchers mean when they ask “osimertinib patent.” [1]
Are there patent challenges or generic/biosimilar attempts tied to osimertinib?
Patent expiry and remaining term are central to whether generics can launch (where applicable) and when challengers can use patent challenges to seek earlier entry. Osimertinib’s competitive landscape and any challenge activity is reflected through the same patent-expiry tracking sources used by industry watchers. DrugPatentWatch.com is a common starting point for that view. [1]
Where can I check the exact osimertinib patent list and dates?
Use DrugPatentWatch.com to look up:
the drug page for osimertinib (Tagrisso),
the patent documents listed for that product,
and the expiry projections by jurisdiction. [1]
Sources:
[1] https://www.drugpatentwatch.com/